Revista Cubana de Medicina
On-line version ISSN 1561-302X
SORIANO GARCIA, Jorge L et al. Paclitaxel-carboplatine scheme assessment applied in patients presenting with metastatic breast cancer. Rev cubana med [online]. 2009, vol.48, n.2, pp. 0-0. ISSN 1561-302X.
Introduction: Paclitex chemotherapy is essential in metastatic breast cancer (MBC). We assessed effectiveness and safety of combined use of carboplatine. Methods: We made a descriptive and retrospective study of 63 patients treated in Oncology Service of "Hermanos Ameijeiras" Surgical Clinical Hospital from January, 2001 to December, 2005 with a histological confirmation of breast cancer, and metastatic disease, previously treated with anthracyclins (in adjuvant therapy). Results: There was a predominance of negative hormonal receptors, and presence of an only metastatic site. Bone and lungs were the more common metastatic locations, 26.4 % and 21.8 %, respectively. Global response rate was of 33.3 %. There were not significant differences in response rate by prognostic variables. Survival at 1, 2, ant 3 years was of 60, 46.4 and 28.2 %, respectively. Survival average was of 16,2 months. Variables associated with a better prognosis were a Karnofsky rate ³ 60 %, positive hormonal receptors and presence of an only metastatic site. Disease disseminated in bone, soft tissues, and skin had a better prognosis. Main toxicities were: hematologic, neurologic, and digestives. The adverse processes average by patient was of 2.6 and the 20 % of these ones were 3-4 degrees. Increment in hepatic enzymes caused a higher level of treatment suspension. Conclusions: Combined schemes with Paclitaxel have a good and acceptable profile of safety and effectiveness.
Keywords : Metastatic breast cancer; chemotherapy; taxanes..